Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
ReShape Lifesciences Inc. (Name of Issuer) |
Common Shares, $0.001 par value per share (Title of Class of Securities) |
76090R309 (CUSIP Number) |
02/18/2025 (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
![]() |
![]() |
![]() |
SCHEDULE 13G
|
CUSIP No. | 76090R309 |
1 | Names of Reporting Persons
Leonite Fund I, LP | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
200,000.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
6.1 % | ||||||||
12 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13G
|
CUSIP No. | 76090R309 |
1 | Names of Reporting Persons
Geller Avi | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
NEW JERSEY
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
200,000.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
6.1 % | ||||||||
12 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13G
|
Item 1. | ||
(a) | Name of issuer:
ReShape Lifesciences Inc. | |
(b) | Address of issuer's principal executive offices:
1001 CALLE AMANECER, SAN CLEMENTE, CALIFORNIA, 92673 | |
Item 2. | ||
(a) | Name of person filing:
This Schedule is being jointly filed by Leonite Fund I LP ("Leonite"), a Delaware limited partnership, and Avi Geller, an individual (each a "Reporting Person" and together, the "Reporting Persons"). | |
(b) | Address or principal business office or, if none, residence:
The principal business address of each Reporting Person is 600 East Crescent Avenue, STE 104, Upper Saddle River, NJ 07458. | |
(c) | Citizenship:
Leonite is a Delaware limited liability company;Mr. Geller is a citizen of the United States of America (state of New Jersey). | |
(d) | Title of class of securities:
Common Shares, $0.001 par value per share | |
(e) | CUSIP No.:
76090R309 | |
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
(a) | ![]() | |
(b) | ![]() | |
(c) | ![]() | |
(d) | ![]() | |
(e) | ![]() | |
(f) | ![]() | |
(g) | ![]() | |
(h) | ![]() | |
(i) | ![]() | |
(j) | ![]() please specify the type of institution: | |
(k) | ![]() | |
Item 4. | Ownership | |
(a) | Amount beneficially owned:
Leonite is the record owner of 200,000 shares of common stock of the Issuer. Mr. Geller is the chief investment officer of Leonite and has sole voting and dispositive power over the shares held by it. As a result, Mr. Geller may be deemed to be an indirect beneficial owner of the shares held directly by Leonite. Mr. Geller disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. | |
(b) | Percent of class:
The 200,000 shares of common stock represent approximately 6.05% of the Issuer's outstanding shares of common stock based on 3,305,087 shares of Common Stock outstanding (excluding the Common Stock underlying the Warrants) as of the completion of the offering referred to in the Issuer's prospectus filed with the Securities Exchange Commission on February 18, 2025. %
| |
(c) | Number of shares as to which the person has:
| |
(i) Sole power to vote or to direct the vote:
200,000 | ||
(ii) Shared power to vote or to direct the vote:
0 | ||
(iii) Sole power to dispose or to direct the disposition of:
200,000 | ||
(iv) Shared power to dispose or to direct the disposition of:
0 | ||
Item 5. | Ownership of 5 Percent or Less of a Class. | |
Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
Item 9. | Notice of Dissolution of Group. | |
Not Applicable
|
Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. |
SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|